The development of our partnerships was an exciting highlight for Cellectis. In March, our partner Iovance Biotherapeutics announced that the U.S. Food and Drug Administration (FDA) allowed an Investigational New Drug Application (IND) to proceed for its first TALEN®-edited Tumor Infiltrating Lymphocytes (TIL) therapy, developed using Cellectis' technology. In April, we received a $20 million convertible note, representing the upfront collaboration consideration under our collaboration agreement with Cytovia Therapeutics. Cellectis is developing custom TALEN® for Cytovia to develop gene-edited iPSC-derived Natural Killer cells.